If the FDA had concerns about elements of the data then they would typically call an Advisory Committee together to seek advice/clarification around those outstanding inquiries. It seems to me that it speaks to the thoroughness of Acadia's submission, but it most certainly was supported by the work done a couple of months ago with parent forums and the input of the various leading Rett organizations. I can only see this as a very good statement.
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.31 |
Change
-0.280(1.92%) |
Mkt cap ! $1.816B | |||
| Open | High | Low | Value | Volume |
| $14.36 | $14.49 | $14.25 | $721.7K | 50.32K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1 | $14.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.32 | 203 | 4 |
View Market Depth
| Last trade - 10.37am 16/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |